Adipotide (FTPP)
Experimental Fat-Targeting PeptidomimeticresearchAlso known as: FTPP, Prohibitin-TP01, Fat-Targeted Proapoptotic Peptide
An experimental peptidomimetic that targets and destroys blood vessels supplying white adipose tissue, causing rapid fat loss through adipose tissue apoptosis in animal studies.
Overview
Adipotide (FTPP — Fat-Targeted Proapoptotic Peptide) is a chimeric peptidomimetic designed to selectively target and destroy the blood supply to white adipose tissue. It consists of two functional domains: a targeting sequence (CKGGRAKDC) that binds prohibitin on the surface of blood vessels supplying fat tissue, and a proapoptotic peptide (D(KLAKLAK)2) that disrupts mitochondrial membranes upon internalization, triggering apoptosis. In a landmark study in obese rhesus monkeys, adipotide caused rapid weight loss of up to 11% in 4 weeks with corresponding improvements in insulin resistance. However, it also caused significant renal toxicity. It remains experimental and has not progressed to human clinical trials. Despite this, it has generated significant interest in the biohacking community as a radical fat-loss approach.
Mechanism of Action
Adipotide works through vascular-targeted adipose destruction: (1) The CKGGRAKDC targeting peptide binds prohibitin expressed on the luminal surface of blood vessels specifically in white adipose tissue; (2) Upon binding, the peptide is internalized via receptor-mediated endocytosis; (3) The D(KLAKLAK)2 proapoptotic domain disrupts mitochondrial membranes; (4) Endothelial cell apoptosis destroys the blood supply to fat tissue; (5) Adipocytes die from ischemia and lack of nutrients; (6) White adipose tissue undergoes resorption and remodeling; (7) The specificity for adipose vasculature is based on differential prohibitin expression.
Molecular Formula
Chimeric peptide (~3kDa)
Molecular Weight
~3000 g/mol
Sequence
CKGGRAKDC-GG-D(KLAKLAK)2 (targeting + proapoptotic domains)
Dosage Protocols
Dose Range
0.5 mg/kg – 1.0 mg/kg
Frequency
Daily (animal studies)
Route
subcutaneous
Cycle Length
4 weeks (primate study)
ONLY animal dosing data exists. The rhesus monkey study used escalating doses. NO human dosing has been established. Underground protocols vary widely and carry unknown risks. Renal toxicity was observed at effective doses.
Source: Barnhart et al., Science Translational Medicine 2011
🧮 Personalized Dosage Calculator
💰 Estimated Pricing
Typical Supply
5mg vial
Last Updated
2026-02
Experimental fat-loss peptide (prohibitin-targeting). Research use only. Significant safety concerns.
⚠️ Prices are estimates based on publicly available data and may vary significantly by vendor, location, and prescription status. This is not medical or financial advice.
Side Effects
| Effect | Severity |
|---|---|
| Renal toxicity | severe |
| Dehydration | moderate |
| Injection site reactions | mild |
| Unknown long-term effects | severe |
Pros & Cons
Dramatic fat loss demonstrated in primate study (11% body weight in 4 weeks)
Novel mechanism of selectively targeting adipose vasculature
Improved insulin sensitivity observed alongside fat loss in animal models
Significant renal toxicity at effective doses — dose-limiting adverse effect
NO human clinical trials or safety data exist
Risk of off-target vascular damage is poorly characterized
Available only from unregulated sources with no quality assurance
Research Studies
🩸 Blood Work
No specific bloodwork requirements reported for this peptide. General health panels are always recommended before starting any peptide protocol.
Legal Status
Experimental compound. Not approved by any regulatory agency. Not in human clinical trials. Available only as a research chemical from select suppliers. Use carries significant unknown risks.
Readers Also Viewed
Semaglutide
99An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
98A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
97A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
95The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.
Related Peptides
Semaglutide
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.